Novo Nordisk Discusses Ozempic, Wegovy, and US Pricing Negotiations

Ozempic and Wegovy Manufacturing

• 🇺🇸 Rebelsis, an oral form of Ozempic for diabetes, has received FDA approval for cardiovascular risk reduction and is manufactured end-to-end in the United States, specifically in Novo Nordisk's North Carolina plant.
• 💊 The company is also anticipating approval for an oral form of Wegovy, which will also be manufactured in their North Carolina facility.

Supply Chain Resilience

• 📈 Following early supply challenges with Wegovy and Ozempic due to unprecedented demand, Novo Nordisk has significantly built up its supply chain.
• 🎯 This preparation includes anticipating increased demand for Rebelsis and the upcoming launch of the oral Wegovy pill, expected around the turn of the year.

GLP-1 Medications and Future Research

• 💡 GLP-1s are compared to generative AI due to the excitement and the numerous indications being explored.
• 🔬 Novo Nordisk has over 25 years of research in obesity and GLP-1s and continues to follow the science to discover new potential uses and educate about their capabilities.

US Drug Pricing and Negotiations

• 🗣️ Novo Nordisk is engaged in active dialogue with the Trump administration regarding Most Favored Nation (MFN) pricing and Medicare drug price negotiations under the IRA.
• 🤝 The company appreciates the focus on patient access and affordability and is open to participating in programs like Trump RX to make medicines available directly to patients.
• 🌍 Implementing MFN pricing in the U.S. could potentially impact drug prices and access in other countries due to differing healthcare systems.